Enzolytics Inc (ENZC)

[Timing101]

Let's Review today's PR Release . It per many did not say anything new , however I say it is VALIDATION of what is to come . Very , Very well thought out, Risk Management , Legal Format and taking next steps to protect value and also making sure all bases are covered.
While not the desired result in Share Price today , it is a VERY, VERY Strong statement ending this year and going into 2021. Charles is not only a strong CEO , but well above the normal CEO of an OTC ticker and he should be looked at that way with out a doubt.
--
===
https://www.otcmarkets.com/stock/ENZC/news/Enzolytics-Inc-2020-Year-End-Update?id=284809
====

Enzolytics, Inc. 2020 Year End Update (Validation recap, do not expect anything else until Jan 2021 is what Charles is saying, but also he is saying all of 2020 is done on info and documentation)
*
Press Release | 12/30/2020
COLLEGE STATION, TX / ACCESSWIRE / December 30, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today shared the following update provided by Enzolytics' CEO Charles Cotropia. The full content of the update is presented below. Just validation who is in charge.

"December 30, 2020 ( End of year , next expect in January , so folks reading this , some said I will wait for the SEC Filings and further validation is all)

To Our Shareholders, ( Validation , we are the new ENZC shareholders)

On September 15, 2020, Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") entered into a non-binding letter of intent to combine the two entities and pursue our joint mission to create therapeutics that are effective and affordable for the treatment of some of the most infectious and deadly diseases in the world, including HIV and the Coronavirus. This goal has as its foundation several components - (1) our patented anti-HIV therapeutics that have been successfully clinically tested, (2) our anti-HIV monoclonal parent antibody previously tested in vitro, demonstrating neutralization of over 95% of the HIV isolates against which it was tested and (3) our proprietary methodology for producing fully human monoclonal antibodies which is being used to produce additional anti-HIV monoclonal antibodies targeting additional immutable sites on the HIV virus as well as multiple anti-CoronaVirus monoclonal antibodies for use as a therapeutic against the SARS-CoV-2 virus.

Both management teams were committed to this mission, and even before the completion of the combination documentation, transition of our organizations began by my appointment to the Enzolytics' Board as a Director and CEO and appointment of Harry Zhabilov to the BCLS Board. This allowed us to share information for assimilating our proprietary information for research and development purposes and for streamlining the administrative function to accelerate future growth.( In other words , terms from a Lawyer like Charles had to be done first.)

On December 1, 2020, the combination agreement was completed, and the control block of shares of Enzolytics was transferred in accordance with the terms of the final document to Dr. Joseph Cotropia, Dr. Gaurav Chandra, and me, officially integrating the management teams and organizations into one single-purposed organization. (This you have to re-read the "Control Block Transfer Agreement here at this link. It does tell you who the designated Bioclonetics Designees were (did not before) with Joseph C and Guarav Chandra. https://backend.otcmarkets.com/otcapi/company/financial-report/265788/content) But Transfer Complete , HUGE

Since the signing of the original non-binding letter of intent, the Company has filed two annual reports and eight quarterly reports, with the required OTC alternative reporting supplemental information, and will soon be filing the last quarterly filing and opinion letter with OTC Markets needed to bring the Company to a current status. The Company is an OTC Market Alternative Standard Reporting entity and is not fully reporting. All of the information that would be required in SEC reporting is included in our Supplemental Information filings and is current. Opinion Letter is the Attorney Letter just fyi.

Currently, the Company has requested proposals from several PCAOB accounting firms to provide quotes for Audits of the Company's current and prior year Financial Statements in order to become fully reporting. Bids were requested to be provided by mid-January, and the Company anticipates making a decision by the end of January 2021.
( This is really HUGE and may not be caught by many , but having a PCAOB oversight brings Validation and also attracts the large Investors and will bring in Big Pharma on the Licensing Side. IT also brings the validation points of going well past "Pink Current" and into higher Tier markets like OTCQB , OTCQX and beyond in the future.
Quote"
" Public Company Accounting Oversight Board
The Public Company Accounting Oversight Board (also known as the PCAOB) is a private-sector, nonprofit corporation created by the Sarbanes-Oxley Act of 2002 to oversee accounting professionals who provide independent audit reports for publicly traded companies.
The PCAOB is a nonprofit corporation established by Congress to oversee the audits of public companies in order to protect investors and further the public interest in the preparation of informative, accurate, and independent audit reports.")

Our new lab is being opened on the campus of Texas A&M University in the University's Institute for Preclinical Studies. Here we will expand our development capabilities for the production of additional monoclonal antibodies targeting immutable sites on the HIV and SARS-CoV-2 viruses. In addition to those primary targets on these viruses already known to us, we have engaged an artificial intelligence (AI) and genetics and molecular biology data science team to curate the thousands of isolates (strains) now known as existing in both the HIV virus and the SARS-CoV-2 virus. This process will allow us to identify conserved, immutable targets against which monoclonal antibodies are to be produced.

The significance of this step is well recognized by experts in virology due to the ability of all viruses to mutate and render ineffective, initially developed therapeutics. We have all now heard of the new variants of the CoronaVirus that have just surfaced this week in the United Kingdom and South Africa. Such variants have been found to now exist in the U.S. Due to mutation, these variants have slightly different structures from the virus as initially introduced into the U.S. and will require different therapeutics to address them. The necessary response to such mutations is to identify sites on the virus that do not mutate - that are immutable - and to produce monoclonal antibodies targeting these immutable sites. Using artificial intelligence, we expect to be able to identify these sites such that antibodies may be produced targeting them. This is one of our focuses.

Testing of the newly produced monoclonal antibodies is also being arranged. This includes testing of our now being produced recombinant anti-HIV monoclonal antibodies created from the parent antibody. Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France.

Dr. Ronald Moss has joined our team as Medical Advisor, adding significant and highly recognized experience. With his assistance, we are advancing our patented antiviral peptide that has been successfully tested in clinical trials at the National Center of Infectious and Parasitic Diseases in Bulgaria. This therapeutic, known as ITV-1, is a suspension of Inactivated Pepsin Fragment (IPF), a purified extract of porcine pepsin. ITV-1 has been shown to strengthen the immune system and may be used to facilitate a broad range of applications. ITV-1 has been tested in HIV patients in a clinical trial conducted under the strict guidelines of the European Union. The Company is in the process of GMP production of the peptide necessary for the validation process, a required step leading to its availability for patient therapy. Regarding the production of the peptide for validation, the Company is reviewing proposals from several CRO labs for such production of this required form of the therapeutic.

Enzolytics has also filed a new U.S. Patent covering an immunotherapy treatment applicable for treating Multiple Sclerosis. The Company is exploring several opportunities to collaborate with other drug development companies to expand our product reach. This product is based on the isolation of nuclear proteins from the spinal cord of a calf and is combined with Interleukin-12. We believe this recombinant protein to have immunomodulatory effect and triggers tissue repair.

In addition to these successes, we have been very successful in raising necessary funding to execute our plans. Our initial $500,000 raise is being followed with $1 million being funded in the next 30 days, and additional investment is being made into the Company by officers of the Company, bringing the total raised since the signing of the non-binding letter of intent to $1.7 million.

The Company has also negotiated a debt exchange whereby most of the existing convertible debt has been exchanged for equity instruments that have a two-year conversion clause to postpone conversions for the next two years. We believe this step, along with the reorganization under Section 251 G that was initiated prior to the closing of the combination agreement, will significantly enhance the equity position of the Company.

By combining our expertise with outside professionals and trusted consultants, we have succeeded in less than three months in accomplishing each of these items - as well as others.

The Company acknowledges the enthusiasm of our investor base, and in response to their desire for up-to-date information, we are updating our website and will be launching it in the New Year.

We, at the Company, look forward to very productive and successful 2021.

Sincerely,

Chares S, Cotropia

CEO, Enzolytics, Inc."